Pharmaceutical 98% Bimatoprost CAS 155206-00-1

CAS:155206-00-1

MF: C25H37NO4

MW:415.57

EINECS:642-890-9

Specification: 99% min Bimatoprost

Sample:Bimatoprost Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Bimatoprost Usage and Synthesis.

Bimatoprost is a prostaglandin drug that was first used to treat eye diseases such as glaucoma under the drug name Lumigan. However, during the course of treatment, patients unexpectedly found that the diameter, length and density of their eyelashes increased significantly. 

After that, bimatoprost was used in clinical trials for eyelash beauty, and its great effect on eyelash thickening and densification directly led to the launch of Lattise by Allergan, the company that produces Lumigan, which was approved by the US FDA in December 2008 as a specialised product for darkening and thickening eyelashes.

Olaparib is effective against Brca1;p53 mammary tumours (intraperitoneal injection at a dose of 50 mg/kg per day), but not against HR-deficient Ecad;p53 mammary tumours.Olaparib does not have dose-limiting toxicity in tumour-bearing mice.Olaparib has been used for the treatment of BRCA-mutated tumours, such as ovarian, breast, and prostate cancers.Olaparib has been used for the treatment of BRCA-mutated tumours. prostate cancer. 

In addition, Olaparib inhibits ATM-deficient tumour cells selectively, suggesting that Olaparib could be a potential reagent for the treatment of ATM-mutated lymphoid tumours.

Uses and functions of Bimatoprost.

Olaparib is a PARP inhibitor that also acts on BRCA1 or BRCA2 mutations.Olaparib has little effect on end-anchor (polymerase)-1 action, with IC50 values greater than.

Olaparib concentrations of 30-100nM act on SW620 cells to inactivate PARP-1. BRCA1-deficient cell lines (MDA-MB-463[1] and HCC1937) were hypersensitive to Olaparib compared to BRCA1- and BRCA2-sufficient cell lines (Hs578T,MDA-MB-231,T47D) Olaparib inhibited PARP and blocked base excision repair, resulting in KB2P cells being 

Olaparib strongly sensitive. This results in a shift from single-strand breaks to double-strand breaks during DNA replication, which activates the BRCA2-dependent recombination pathway.

Adverse Reaction of Bimatoprost.

(1) Deepening of iris colour, blepharitis, symptoms of eye irritation and pain; darkening, thickening and growth of eyelashes; conjunctival congestion, temporary punctate corneal epithelial eruptions, eyelid oedema and erythema; rash.

(2) Rarely respiratory disturbances, aggravation of asthma, iritis, uveitis, darkening of eyelid skin.

(3) Very rarely chest pain, pharyngitis.

(4) Eye itching, allergic conjunctivitis, cataracts, conjunctival oedema, discharge, photophobia, superficial punctate keratitis, headache, hypertension.

Pharmacological Effect of Bulk Bimatoprost.

It is a synthetic prostamide, a structural analogue of prostaglandins with IOP-lowering activity, which selectively mimics the action of naturally occurring prostamides. It is currently believed that this product lowers intraocular pressure (IOP) by increasing the outflow of atrial fluid through both the trabecular meshwork and uveoscleral pathways. High IOP is a major contributor to glaucomatous visual field defects, and the higher the IOP, the greater the risk of optic nerve damage and visual field defects.